echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The use of DNA biomarkers to detect early HPV-positive oropharyngeal cancer has limitations

    The use of DNA biomarkers to detect early HPV-positive oropharyngeal cancer has limitations

    • Last Update: 2022-11-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
      

    Oropharyngeal cancer caused by human papillomavirus (HPV) has risen sharply in recent years, replacing tobacco use and alcohol abuse as the main drivers of
    new cases.
    Fortunately, HPV-positive oropharyngeal cancer has a higher survival rate compared to other head and neck cancers, and lower-intensity treatment options can be employed, especially when diagnosed early
    .
    Circulating tumor HPV DNA (ctHPV DNA), a promising biomarker for early diagnosis and prediction of recurrence, is found in the blood of nearly 90% of HPV-positive oropharyngeal cancer patients and can be detected
    using commercially available blood tests to measure HPV DNA (TTMV-HPV DNA) in tumor cells.
    However, in one study
    of 110 patients with HPV-positive oropharyngeal cancer.
    Researchers from Brigham and Women's Hospital (one of the founding members of Brigham Health System) found that TTMV-HPV DNA levels correlated with the presence of cancer in the lymph nodes and were often undetectable
    in patients without neck masses.
    This has huge implications for how the test is interpreted and applied to early-stage disease, potentially meaning that it is not effective
    for screening and early diagnosis of this increasingly common disease.

    "ctHPV DNA testing is becoming a powerful tool for the diagnosis, treatment, and post-treatment surveillance of HPV-positive oropharyngeal cancer," said
    Eleni M.
    Rettig, Ph.
    D.
    , first author of the Department of Otolaryngology, Head and Neck Surgery and Dana-Farber Cancer Institute at Brigham and Women's Hospital.
    Rettig is also an affiliated faculty member
    of the Center for Surgery and Public Health.
    "It's increasingly important to
    understand the advantages and limitations of this type of testing.
    "


    Association of Pretreatment Circulating Tumor Tissue–Modified Viral HPV DNA With Clinicopathologic Factors in HPV-Positive Oropharyngeal Cancer


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.